Back to Research Hub
Dianthus Therapeutics, Inc.
DNTH
$84.57+3.35 (+4.12%)
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases.
StreetsValue research for Dianthus Therapeutics, Inc. (DNTH)
Members get the full report for Dianthus Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.